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’INTRODUCTION
Over 170 million people, approximately 3% of the world’s
population, are infected with the hepatitis C virus (HCV).
1
Infection with this virus can result in hepatic ﬁbrosis which can
progress to cirrhosis and hepatocellular carcinoma. Liver biopsy
is the gold standard for the diagnosis and prognosis of hepatic
ﬁbrosis,
2 but this approach is costly, invasive, painful, and
unreliable if the scarring in the liver is not homogeneous or
biopsiesunder10mmareanalyzed.
2,3Currentserumbiomarkers
only eliminate the need for biopsies in 26% of cases.
4 More
reliablenoninvasivemarkerstoreplaceliverbiopsywouldbeneﬁt
patients and practitioners alike.
Bloodproteinswhoseexpressionlevelschangewithincreasing
ﬁbrosiscould beusedaslessinvasivebiomarkerswhichareeasily
obtainable. Such novel serological markers could be identiﬁed
using proteomics to separate serum or plasma and identify the
diﬀerentially expressed proteins. However, the wide dynamic
range of protein concentrations which span over 10 orders of
magnitude in serum and plasma, poses a signiﬁcant problem for
proteomic analysis. Highly abundant proteins, especially albu-
min, immunoglobulins and transferrin, restrict protein load on
gels for electrophoresis and limit the detectionof low abundance
proteins.
5 Despite this we have previously used two-dimensional
gel electrophoresis (2-DE) over the wide pH 3 10 range to
identify several novel candidate serum biomarkers for liver
ﬁbrosis.
6 To address the problem posed by highly abundant
proteins, here we use 2-DE over a narrow pH 3 5.6 range since
thisliesoutsidetherangeofhighlyabundantalbumin,transferrin
and immunoglobulins. This enables the loading of four times
more protein than in our previous ﬁbrosis marker study, and
considerablyenhancesrepresentationoflowabundancefeatures.
We present signiﬁcantly improved gel-based separation of the
acidicproteomeandhaveidentiﬁedlowabundantfeatureswhich
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ABSTRACT: Despite many shortcomings, liver biopsy is
regarded as the gold standard for assessing liver ﬁbrosis. A less
invasiveandequallyormorereliableapproachwouldconstitute
a major advancement in the ﬁeld. Proteomics can aid discovery
ofnovelserologicalmarkersandtheseproteinscanbemeasured
inpatientblood.Amajorchallengeofdiscoveringbiomarkersin
serumisthepresenceofhighlyabundantserumproteins,which
restrictsthelevelsoftotalproteinloadedontogelsandlimitsthe
detection of low abundance features. To overcome this pro-
blem,weusedtwo-dimensionalgelelectrophoresis(2-DE)over
a narrow pH 3 5.6 range since this lies outside the range of
highly abundant albumin, transferrin and immunoglobulins. In
addition, we used in-solution isoelectric focusing followed by
SDS-PAGE to ﬁnd biomarkers in hepatitis C induced liver cirrhosis. Using the pH 3 5.6 range for 2-DE, we achieved improved
representation of low abundance features and enhanced separation. We found in-solution isoelectric focusing to be beneﬁcial for
analyzing basic, high molecular weight proteins. Using this method, the beta chains of both complement C3 and C4 were found to
decrease in serum from hepatitis C patients with cirrhosis, a change not observed previously by 2-DE. We present two proteomics
approaches that can aid in the discovery of clinical biomarkers in various diseases and discuss how these approaches have helped to
identify 23 novel biomarkers for hepatic ﬁbrosis.
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were below the detection threshold in the study using the wide
pH 3 10 range. We also examine the basic serum proteome for
ﬁbrosis markers using in-solution isoelectric focusing (IEF)
followed by SDS-PAGE and discuss the beneﬁt of this approach
over 2-DE for basic high molecular weight proteins. Using this
approach we have identiﬁed the beta chains of both complement
C3 and C4 as candidate ﬁbrosis markers which were not observed
p r e v i o u s l yb y2 - D E .
The two proteomic approaches shown in this study can aid
clinical biomarker discovery not only for hepatic ﬁbrosis but
many other diseases.
’EXPERIMENTAL SECTION
2-DE
Oneand2mgofpoolednormalhumanserum(Sigma,Dorset,
UK) were separated using 18 cm pH 3 10, pH 5 6, pH 3 5.6
nonlinear (NL) and pH 6 11 immobilized pH gradient (IPG)
strips (GE Healthcare, Bucks, U.K.). Samples were made up to
375 μLinIEFrehydrationbuﬀer (5 Murea,2Mthiourea, 2mM
tributyl phosphine, 65 mM DTT, 4% (w/v) CHAPS, 150 mM
nondetergentsulfobetaine256(NDSB-256)and0.0012%(w/v)
bromophenolblue).2-DEwasperformed asdescribedearlier for
the pH 3 10 gels.
6 Gels covering the other pH ranges were also
run in the same way except with 1.8% (v/v) pH 5 6, pH 3 6
and pH 6 11 ampholytes (SERVALYT, SERVA, Heidelberg,
Germany) for the pH 5 6 NL, pH 3 5.6 and pH 6 11 strips,
respectively. Samples were left overnight to rehydrate 18 cm pH
3 5.6NLIPGDryStrips(GEHealthcare,Bucks,U.K.).IEFwas
carried out for 75 kVh at 17 C. Strips were incubated in
equilibration solution (4 M urea, 2 M thiourea, 50 mM Tris-
HCl (pH 6.8), 30% (v/v) glycerol, 2% (w/v) SDS, 130 mM
DTT, 0.002% (w/v) bromophenol blue) for 15 min. Proteins
were separated by 9 16% (w/v) SDS-PAGE gradient gels using
20mApergelfor1h,followed by40mAper gelfor4hat10C.
Following electrophoresis, gels were ﬁxed in 40% (v/v) ethanol
and 10% (v/v) acetic acid and stained with the ﬂuorescent dye
OGT1238.
7Althoughthisdyeisproprietary,itissimilartoother
commercialdyessuchasSyproRubyorSyproOrange whichcan
be used as alternatives. Gels were scanned using an Apollo II
linear ﬂuorescence scanner (Oxford Glycosciences, Abingdon,
U.K.) to obtain 16-bit images at 200 μm resolution. This Apollo
II scanner is custom built but any imager which can image
ﬂuorescently stained gels, such as the Fuji LAS range of cameras,
could be used as alternatives. Features were detected using a
custom version of the Melanie II software (Oxford Glycos-
ciences, Abingdon, UK).
7 Although customized, the software
wasonlyusedtocurate spotsanddeterminethenumberofspots
per gel which can be done with any commercially available
software such as Melanie 7. Artifacts were removed and features
were manually edited if spot splitting was required. Serum (500
μg) was also resolved by 2-DE using pH 3 10 NL IPG strips as
previously described.
6
In-Gel Digestion and Peptide Extraction
Diﬀerentially expressed bands on the SDS-PAGE gels were
assignedfor mass spectrometricanalysis. The bands on the SDS-
PAGEgelswereexcisedmanuallyanddriedinaSpeedVac.In-gel
trypsin digestion was carried out manually according to the
protocolofShevchenkoandco-workers.
8Digestedsampleswere
lyophilizedand dissolved in0.1% (v/v) formicacidprior tomass
spectrometric analysis.
Mass Spectrometric Analysis
Tryptic peptides were analyzed using a Q-TOF 1 mass
spectrometer coupled to a CapLC (Waters, Hertfordshire, U.K.).
Peptideswereconcentratedanddesaltedona300μmI.D./5mm
C18 precolumn and resolved on a 75 μm I.D./25 cm C18
PepMap analytical column (LC packings, Sunnyvale, CA) with a
45min5 95%(v/v)acetonitrilegradientcontaining0.1%(v/v)
formicacidataﬂowrateof200nL/min.Spectrawereacquiredin
positive mode. MS to MS/MS switching was controlled in an
automaticdata-dependentfashionwitha1ssurveyscanfollowed
by three 1 s MS/MS scans. Ions selected for MS/MS were
excluded from further fragmentation for 2 min. Raw MS/MS
spectra were smoothed and centered using ProteinLynx Global
server 2.1.5, spectra were not deisotoped. Processed peak list
(.pkl)ﬁlesweresearchedagainsttheSwiss-Protdatabase(release
54.4)usingMASCOT(MatrixScience,London,U.K.).Searches
were restricted to the human (17565 sequences) and virus
(11132 sequences) taxonomies. Carbamidomethyl cysteine
was deﬁned as a ﬁxed modiﬁcation and oxidized methionine as
avariablemodiﬁcation.Dataweresearchedallowing0.5Daerror
to accommodate calibration drift and up to 2 missed tryptic
cleavage sites. All data were checked for consistent error dis-
tribution and all positive identiﬁcations were checked manually.
In-Solution IEF
Healthy control and cirrhotic blood samples were collected in
Serum Separator Tubes (BD, Oxford, U.K.). Patients were age
and sex matched (males in 30s). The patients were recruited
from the John Radcliﬀe Hospital, Oxford, U.K. and cirrhosis
was determined using the Ishak scoring method as previously
described.
9 These scores along with the ages and gender are
displayed in Supporting Table 1, Supporting Information. Col-
lection of patient samples for this study was approved by the
Central Oxford Research Ethics Committee (No. 98.137) and
consentwasobtainedfromeachpatient.SeraweredilutedinIEF
rehydration buﬀer with 1.8% (v/v) pH 3 10 carrier ampholytes
and 0.002% (w/v) bromophenol blue to a ﬁnal protein concen-
tration of 298.5 μg/mL. In-solution IEF was performed as
previously described
10,11 using an IEF fractionator (Invitrogen,
Paisley, U.K.) with the following pH ranges in each fractionation
chamber: pH 3 4.6; pH 4.6 5.4; pH 5.4 6.2; pH 6.2 7; pH
7 10. The anode buﬀer was prepared with 7 M urea, 2 M
thiourea and Novex IEF Anode buﬀer pH 3.0 (Invitrogen). The
cathode buﬀer was prepared with 7 M urea, 2 M thiourea and
Novex IEF Cathode buﬀer pH 10.4 (Invitrogen). Anode and
cathode buﬀers (17.5 mL each) were loaded into the respective
electrodereservoirsoftheIEFfractionator.670μLofthediluted
serum samples were added to the ﬁve fraction chambers. Frac-
tionation was performed using 100 V for 20 min, 200 V for
80 min and 600 V for 80 min at 2 mA and 2 W. Detergents and
salts were removed from the samples by chloroform methanol
precipitation as previously described for in-solutionIEF
12 before
being resolved by 4 12% (w/v) NuPAGE Bis-Tris-HCl SDS-
PAGE (Invitrogen) according to the manufacturer’s recommen-
dation. The intensity of gel bands for healthy control were
compared to cirrhotic serum using Advanced Image Data
Analyzer software (Raytest, Straubenhardt, Germany).
’RESULTS
2-DE Optimization
Narrow range IPG strips with the ranges pH 6 11, pH 5 6
and pH 3 5.6 along with wide range pH 3 10 IPG strips were2645 dx.doi.org/10.1021/pr101077c |J. Proteome Res. 2011, 10, 2643–2650
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Figure1. Optimisationof2-DEseparationofhumanserumproteinsusingnarrowrangeIPGstrips.Gelswererunwith(A)pH6 11,(B)pH5 6,and
(C) pH 3 5.6 NL IPG strips. In each case, 1 mg was separated using a narrow range IPG strip (left), 2 mg was separated using the same narrow range
IPG strip (middle)and 500 μg separated usingpH 3 10NL IPG strips with thenarrow pHrange investigated highlighted within adashedbox (right).2646 dx.doi.org/10.1021/pr101077c |J. Proteome Res. 2011, 10, 2643–2650
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usedtoseparate1and2mgofnormalhumanserum.Thesegelswere
comparedwith 500 μg ofnormalhumanserumloaded onpH3 10
strips, as used in our previous study,
6 (Figure 1). The pH 3 5.6
range with a load of 2 mg showed the best separation with almost
twice as many features as a pH 3 10 gel across the same pH 3 5.6
range (Supporting Figure 1, Supporting Information). A spot
number count on the Melanie II software showed that the pH
3 5.6rangewitha2mgloadhad551featureswhereasthepH3 10
gel with a 500 μg load had only 289 features across the same pH
3 5.6 range. The total spot number count on the 500 μgp H3  10
g e lw a s5 2 3 ,l e s st h a nt h et o t a lf e a t u r ec o u n to nt h ep H3  5.6 gel.
Spots which were well separated in the 500 μgp H3  10 gel were
merged together in the pH 3 10 gels with 1 and 2 mg of serum.
In-Solution IEF
Healthy control and cirrhotic serum samples were separated
by in-solution IEF into ﬁve diﬀerent pH ranges using an IEF
fractionator. Figure 2 shows an SDS-PAGE gel with the ﬁve
fractions from the IEF fractionator where the band proﬁle seen
by SDS-PAGE resembles that of a pH 3 10 2-DE gel since the
fractions range from pH 3 to 10. Figure 3 shows each fraction
resolved by SDS-PAGE highlighting the diﬀerentially expressed
bandsbetweenthehealthycontrolandcirrhoticsamples.Aswith
our previous 2-DE analysis,
6 the following changes were ob-
servedincirrhoticserumwithrespecttohealthycontrolserum:a
decrease in haptoglobin, an increase in alpha 2 macroglobulin,
and an increase in IgG (both heavy and light chains). Consistent
withthe2-DEresults,otherfragmentsofcomplementC3andC4
were found to be more abundant in the serum of controls than
cirrhotic patients. In the pH 7 10 fraction, diﬀerentially ex-
pressed bands at approximately 75 kDa on the gel contained
peptides derived from complement C3 and C4, which in both
cases span their β-chains (Supporting Figure 2, Supporting
Figure2. SerumbandingpatternfortheIEFfractionatorfractionsrunbySDS-PAGEshowsasimilarproﬁletothespotsseenby2-DE.(A) Serumwasseparated
by9 16% 2-DE with pH 3 10 NL IPG strips using a load of 500 μg. The gel was calibrated with landmarks of known pI and molecular weight. (B) Serumwas
separatedusingin-solutionIEFintoﬁvefractions(F1=pH3 4.6;F2=pH4.6 5.4;F3=pH5.4 6.2;F4=pH6.2 7;F5=pH7 10).Eachfractionwasrunby
SDS-PAGE alongside unfractionated serum (U). M = Molecular weight markers (225, 150, 100, 75, 50, 35, 25, 15, 10 kDa). The ﬁve fractions from the IEF
fractionator span pH 3 to pH 10 and therefore the banding pattern seen by SDS-PAGE is similar to the spot proﬁle seen using a pH 3 10 2-DE gel.2647 dx.doi.org/10.1021/pr101077c |J. Proteome Res. 2011, 10, 2643–2650
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Information). The protein score, sequence coverage and pep-
tides identiﬁed for these complement proteins are shown in
Table 1. In-solution IEF and SDS-PAGE were repeated for
additional samples followed by gel band densitometry (Sup-
porting Figure 3A, Supporting Information). This data shows
that the higher molecular weight band, which contains comple-
ment C3 beta but predominantly C4 beta (Table 1), is clearly
expressed to a higher extent in controls compared to cirrhosis
when analyzing multiple samples (Supporting Figure 3B, upper
panel). The lower molecular weight band containing comple-
ment C4 beta and predominately C3 beta (Table 1) is seen in
both controls and cirrhosis but expressed to a higher extent in
controls (Supporting Figure 3B, lower panel). To validate these
candidate cirrhosis markers, unfractionated control and cirrhosis
samples were blotted for complement C3 beta and C4 beta
(Supporting Figure 3C). Blot band densitometry showed a clear
decrease for both complement C3 beta and C4 beta, the results
being more consistent for complement C4 beta with lower
standard deviation (Supporting Figure 3D). The in-solution
IEF fractions from control serum were also separated by 2-DE
to conﬁrm fractionation (Supporting Figure 4, Supporting
Information). The results show that the IEF fractionator does
not give a clear-cut fractionation but is able to reproducibly
enrich proteins in the pH range of the fraction.
’DISCUSSION
Individuals infected with HCV can develop hepatic ﬁbrosis
which can progress to liver cirrhosis and hepatocellular carcino-
ma.Currentlythemostreliablewayofassessingliverﬁbrosisisby
biopsy and so there is an urgent need for less invasive serological
biomarkers. In this study we use two novel proteomics ap-
proaches which can aid biomarker discovery for all diseases
includingliverﬁbrosis.Theuseofin-solutionIEFrevealsthebeta
chains of both complement C3 and C4 to be decreased in
cirrhosis.
A major diﬃculty for discovering novel biomarkers in serum
and plasma is the presence of highly abundant proteins which
limits the detection of low abundant features and restricts the
amountoftotalproteinloadedontogels.
5BothalbuminandIgG
alonemakeupmorethan75%ofthetotalplasma/serumprotein
content.
13 To overcome this obstacle in ﬁnding biomarkers
several groups have tried prefractionation strategies to deplete
high abundance proteins from samples prior to electrophoresis
and thus improve the representation of low abundant proteins.
Antibody-based immunoprecipitation methods appear to be
most suitable for removal of highly abundant proteins and we
have successfully performed this in the past to identify a novel
biomarker for uveal melanoma by removing twelve of the more
abundant serum proteins.
14 We achieved this using chicken IgY
antibodies since they oﬀer broader host antigen binding and
cleaner capture than IgG methods due to the greater evolution-
ary distance between chickens and mammals. However, immu-
noprecipitation is expensive due to the vast amount of antibody
required to deplete these highly abundant proteins. Less expen-
sive options for the removal of albumin include using Cibacron
Blue-based prefractionation approaches. These dye-aﬃnity
methods have been compared alongside immunoprecipitation
and are less eﬃcient and less speciﬁc causing unwanted removal
of a large number of nonalbumin proteins,
15 possibly including
potential biomarkers. Unlike the large amount of protein used in
this study(2 mg), it is very challenging to load similar high levels
of protein post depletion for multiple samples due to the low
recovery rates during the removal of highly abundant proteins as
well as losses during concentration.
Serumproteinloadsof1and2mgwereinvestigated,thelatter
being the maximum load recommended by the manufacturer for
preparative IEF using 18 cm IPG strips. For the narrow pH
ranges investigated, Figure 1 shows improved representation of
low abundant features for 2 mg serum compared to 1 mg serum.
In the case for pH 3 10 gels, features which were well separated
using a load of 500 μg were merged together when using the
higher 1 and 2 mg loads due to overloading indicating that this
widepHrangeisunsuitableforhighproteinloads.ThepH6 11
rangeshowednoimprovementoverourpreviouspH3 10gels
6
in this alkaline region possibly due to the presence of highly
abundant IgG and transferrin. Also, basic proteins are poorly
represented by 2-DE due to their reduced solubility. The
reducing agent we used in this study, dithiothreitol, becomes
Figure 3. In-solution IEF combined with SDS-PAGE allows improved
representation ofhighmolecularweightbasicproteins.Normalcontrols
(N) and cirrhotic (C) serum samples were fractionated by in-solution
IEF. The resulting ﬁve fractions from the IEF fractionator were then
separatedby4 12%(w/v)SDS-PAGEalongsideunfractionatedserum.
A) A typical proﬁle observed for human serum. The dashed box region
indicates the serum proﬁle that is comparable to a pH 3 10 2-DE gel
(see Figure 3). H = high molecular weight basic proteins that are not as
well represented by 2-DE. B) Diﬀerential analysis of the SDS-PAGE
lanes comparing controls with cirrhotic serum for each of the fractions.
U = Unfractionated serum; 1 = pH 3 4.6; 2 = pH 4.6 5.4; 3 = pH
5.4 6.2; 4 = pH 6.2 7; 5 = pH 7 10; M = Molecular weight markers;
H-b = Haptoglobin β-chain; H-a = Haptoglobin R-chain; a2M = R2
macroglobin;C3/4b=β-chainsofcomplementC3andC4.Bands1and
2 show the bands containing the complement proteins and the number
of MS/MS peptide matches, percentage sequence coverage and protein
score for these bands are shown in Table 1.2648 dx.doi.org/10.1021/pr101077c |J. Proteome Res. 2011, 10, 2643–2650
Journal of Proteome Research TECHNICAL NOTE
negatively charged during IEF and migrates toward the anode
thereby decreasing the concentration of dithiothreitol in the
basic end of the strip. These unreduced proteins have decreased
solubility resulting in streaking in the basic region of the 2-DE
gel.
16 This particularly aﬀects basic proteins which have a high
molecular weight, since they have diﬃculty in entering the
second dimension gel matrix from the IEF strip.
17
The pH 5 6 range, although covering the main isoform of
albumin, did display improved separation of proteins but with
only a few additional features not previously seen in the wide
range pH 3 10 analysis.
6 All of these additional features had
already been observed in the pH 3 5.6 gels, therefore this pH
range did not warrant complete analysis.
The use of narrow range IPG strips in a range outside the
isoelectric points of the main isoforms of the most abundant
plasma/serum proteins would enable greater protein loads
thereby increasing the representation of low abundant features.
The three most abundant plasma/serum proteins are albumin,
IgG and transferrin. Serum was separated using a wide pH 3 10
NL IPG strip (Figure 1) and the isoelectric point ranges of the
main isoforms of albumin, IgG and transferrin were determined
using calibratedlandmarks as pH 5.6 5.9, 6.3 8.5 and6.2 6.5,
respectively, which is consistent with previously reported 2-DE
data.
18 The pH range of these three most abundant plasma/
serum proteins were above pH 5.6 which may explain why the
pH 3 5.6 NL range chosen for analysis led to superior separa-
tion and highest feature number.
Some albumin “bled over” into the pH 3 5.6 range when
usingaserumloadof2mg,althoughthiswasnoworsethanwhat
we observed in our previous study.
6 We judged the gain in low
abundance featureswiththe higher protein load tooutweighthis
problemandtheloadof2mgwaschosenfordeterminingﬁbrosis
biomarkers using these narrow range IPG strips. The pH 3 5.6
range with a load of 2 mg appeared to be the best narrow pH
range forbiomarkerdiscovery.ThispH range allowedfourtimes
more protein to be loaded (2 mg) than in our previous study
6
(500μg),whichallowedvisualizationofseveralnewlowabundant
features. Also the narrow pH range helped to increase the
separation oftheacidicplasma/serumproteome.The separation
achieved in this pH range appeared to be better than previous
large scale 2-DE studies for identifying the human serum
proteome
19 showing new features that were previously not
observed by 2-DE. Therefore not only is this pH range better
forbiomarkerdiscoverybutitalsomayrevealnewserum/plasma
proteins that were previously not detected by 2-DE. To prove
that this pH range was suitable for biomarker discovery, plasma
samples from healthy control individuals and patients with HCV
induced cirrhosis were compared using 2-DE over this range to
identify novel biomarker candidates for hepatic ﬁbrosis in
hepatitis C patient.
20 Using this pH 3 5.6 range 21 novel
candidate ﬁbrosis biomarkers were identiﬁed which were not
seen in our previous study using the pH 3 10 range. This
conﬁrms that the pH 3 5.6 range helps in the discovery of
clinical biomarkers for hepatic ﬁbrosis and would be advanta-
geous in determining novel serological markers for other diseases.
The pH 3 5.6 range used in this study only covers the acidic
proteome and therefore any biomarkers present in the alkaline
region would be missed. The pH 6 11 range was investigated
(Figure 1) but this range showed no improvement to the basic
area compared to our previous study
6 and high molecular weight
basic proteins are poorly resolved by 2-DE. These diﬃculties
with basic and high molecular weight proteins are not encoun-
tered with SDS-PAGE, a technique with lower resolution. To
attainahigherresolutionwhiletakingadvantageofthebeneﬁtsof
SDS-PAGE, we decided to fractionate serum samples by pH
priortoelectrophoresis.Althoughthecombinationofin-solution
IEF and SDS-PAGE has previously been reported,
21 we indicate
for the ﬁrst time that this approach is beneﬁcial for analyzing
basic, high molecular weight proteins. SDS-PAGE analysis of
unfractionated control and cirrhotic serum appeared to show no
diﬀerence in diﬀerential band analysis due to the low resolution
separation of this technique. However, by combining the in-
solutionIEFmethodwiththeSDS-PAGEapproach,theproteins
were separated toan extent which allowed to discern diﬀerences.
Table 1. Diﬀerentially Expressed Complement Proteins Identiﬁed in Serum Samples of Controls versus Cirrhotic Patients
a
band protein name no. of peptides peptides sequence coverage (%) protein score
1 Complement C4 6 LLLFSPSVVHLGVPLSVGVQLQDVPR 5.21 277.29
HLVPGAPFLLQALVR
TTNIQGINLLFSSR
GHLFLQTDQPIYNPGQR
RGHLFLQTDQPIYNPGQR
AVGSGATFSHYYYMILSR
Complement C3 4 EPGQDLVVLPLSITTDFIPSFR 4.50 205.37
TELRPGETLNVNFLLR
IPIEDGSGEVVLSR
TMQALPYSTVGNSNNYLHLSVLR
2 Complement C3 5 TMQALPYSTVGNSNNYLHLSVLR 4.69 304.64
IPIEDGSGEVVLSR
QVREPGQDLVVLPLSITTDFIPSFR
TELRPGETLNVNFLLR
EPGQDLVVLPLSITTDFIPSFR
Complement C4 2 LLLFSPSVVHLGVPLSVGVQLQDVPR 2.35 100.36
HLVPGAPFLLQALVR
aBands1and2showninFigure3weredecreasedincirrhosis.ThenumberofMS/MSpeptidematches,percentagesequencecoverageandproteinscore
were determined by the Mascot Daemon search engine.2649 dx.doi.org/10.1021/pr101077c |J. Proteome Res. 2011, 10, 2643–2650
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ChangesincomplementC3andC4wereobservedinthehigh
molecular weight basic fraction (pH 7 10). To conﬁrm the
reproducibility of this data, in-solution IEFand SDS-PAGE were
repeated for additional samples followed by gel band densitom-
tery (Supporting Figure 3A, Supporting Information) which
showed that the changes in both bands containing C3 and C4
beta were consistent. These additional samples were not
matched to any category such as age or sex (Supporting Table
1,SupportingInformation).Thepointandadvantageofthiskind
of marker ﬁnding exercise is that biomarkers should not be
dependent on these categories and so we aimed to eliminate any
groupspeciﬁchitsfromtheoutset.Wehavepreviouslyidentiﬁed
21 markers for liver ﬁbrosis which were not dependent on age or
sex.
20 The changes in complement C3 and C4 beta were not
observed by 2-DE analysis due to the problem with reduced
solubility of basic proteins, demonstrating an advantage of the
combined in-solution IEF and SDS-PAGE approach over solely
gel-basedtechnologies.ThetheoreticalpIoftheβ-chainforC4is
pH 8.7, which is consistent with the pH 7 10 range for this
fraction.ThetheoreticalpIoftheβ-chainforC3wasdetermined
tobepH6.8whichismarginallyoutsidetherangeofthisfraction
but this was expected since we found that the IEF fractionator
enriches proteins rather than providing a clear-cut fractionation
forthepH range; however,asproteinsare enriched reproducibly
this poses no problem. The diﬀerentially expressed band im-
mediately below the 75 kDa also contained sequences within the
β-chains of both C3 and C4 but these were fragments since the
bandwasatalowermolecularweight.Thisbandwasseeninboth
control and cirrhosis samples but expressed to a higher extent in
control samples, whereas the higher molecular weight band which
was diﬀerentially expressed appeared only in control samples
(Figure 3 and Supporting Figure 3A, Supporting Information).
This lower molecular weight band contained predominantly com-
plement C3 beta (Table 1) and showed a clear but less consistent
change among multiple samples when validated by Western blot
(Supporting Figure 3C and D). The more clearly changing higher
molecular weight band contained predominantly complement C4
beta (Table 1) and showed a clear and consistent change among
multiple samples when validated by Western blot (Supporting
Figure 3C and D). This suggests that complement C4 beta may
be a better biomarker for cirrhosis than complement C3 beta and
would need to be validated using a larger number of samples.
’CONCLUSION
Thisstudyshowshowtwodiﬀerentproteomicapproachescan
aidinthediscoveryofdiseasebiomarkers.Toourknowledgethis
is the ﬁrst time the pH 3 5.6 range has been used to separate
serumby2-DEandwehaveshownthatthispHrangeisusefulfor
discovering novel biomarkers in diseases. We have also shown
that the use of in-solution IEF followed by SDS-PAGE improves
the separation of the basic proteome thereby helping to identify
disease biomarkers in the basic region of plasma and serum
proteomes. Using this approach we show that the beta chains of
complementC3andC4decreaseinserumfromhepatitisCpatients
with cirrhosis, a change not observed previously by 2-DE.
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Images of a pH 3 10 and pH 3 5.6 gel with spot numbers,
complement C3 and C4 peptide sequence information, in-solution
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